Not Yet Recruiting PHASE4 INTERVENTIONAL 3-arm
NCT07322068
Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PMC-VAC)
Sponsor: Infectious Diseases Research Collaboration, Uganda
Conditions
Malaria, Falciparum
Interventions
Dihydroartemisinin Piperaquine Dihydroartemisinin Piperaquine Placebo Sulfadoxine pyrimethamine + Amodiaquine Sulfadoxine pyrimethamine + Amodiaquine placebo
Updated 1 time since 2026 Last updated: Jan 6, 2026 Started: Sep 30, 2026 Primary completion: Jun 30, 2033 Completion: Jun 30, 2033
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE4 clinical study on Malaria, Falciparum, this trial is actively recruiting participants. The trial is conducted by Infectious Diseases Research Collaboration, Uganda and has accumulated 1 data snapshot since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Infectious Diseases Research Collaboration, Uganda
- National Institute of Allergy and Infectious Diseases (NIAID)
- Stanford University
- University of California, San Francisco
Data source: Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .